OSE Immunotherapeutics Highlights Abstracts Selected for Presentation at ASCO 2025
OSE Immunotherapeutics Highlights Abstracts Selected for
Presentation at ASCO 2025
Featuring proprietary asset Tedopi® and two partnered SIRPα inhibitor assets with Boehringer Ingelheim
NANTES, France – April 23, 2025, 6:00 p.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announced that several abstracts highlighting the Company's innovative assets have been selected for presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from June 1-5, 2025, in Chicago, Illinois.
The abstracts feature both proprietary and partnered assets, showcasing OSE Immunotherapeutics' commitment to advancing cancer treatment through cutting-edge research and strategic collaborations addressing multiple cancer types.
Highlights:
- Proprietary Asset: Tedopi® (OSE-2101) cancer vaccine: Trial in Progress for ARTEMIA Phase 3 trial in Non-Small Cell Lung Cancer; Oral Presentation for TEDOPaM Phase 2 trial topline results in pancreatic cancer, presented by the study’s sponsor GERCOR Group.
- Partnered Assets: SIRPα antagonists BI 765063 and BI 770371, an improved next generation SIRPα inhibitor, developed in partnership with Boehringer Ingelheim: Rapid Oral Abstracts of the Phase 1 results for BI 765063 and BI 770371 presented by Boehringer Ingelheim, OSE Immunotherapeutics’ partner.
| Tedopi® (OSE-2101) cancer vaccine in ARTEMIA Phase 3 trial – OSE IMMUNOTHERAPEUTICS | |
| Abstract Number Poster Board Number | TPS8651 129a |
| Title | “Phase 3 trial of the therapeutic cancer vaccine OSE2101 versus docetaxel in patients with metastatic non-small cell lung cancer and secondary resistance to immunotherapy” |
| Session Type and Title | Poster Session – Lung Cancer — Non-Small Cell Metastatic |
| Date and time | May 31, 2025 - 1:30 PM - 4:30 PM CDT |
| Tedopi® (OSE-2101) cancer vaccine in TEDOPaM Phase 2 trial – OSE IMMUNOTHERAPEUTICS | |
| Abstract Number | 4009 |
| Title | “Maintenance with OSE2101 plus FOLFIRI vs FOLFIRI alone after FOLFIRINOX (FFX) induction in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC): Primary endpoint results of a randomized TEDOPAM GERCOR D17-01 PRODIGE 63 trial” |
| Session Type and Title | Clinical Science Symposium – Innovative Biomarkers and Vaccines in Pancreatic Cancer Session |
| Date and time | June 2, 2025 - 8:00 AM - 9.30 AM CDT |
| BI 770371 – Phase 1 trial - BOEHRINGER INGELHEIM | |
| Abstract Number | 2515 |
| Title | “An open-label, Phase I trial of the SIRPα monoclonal antibody, BI 770371, alone and in combination with ezabenlimab in patients with advanced solid tumors” |
| Session Type and Title | Rapid Oral Abstract - Developmental Therapeutics - Immunotherapy |
| Date and time | June 1, 2025 - 11:15 AM - 12:45:PM CDT |
| BI 765063 – Phase 1b trial - BOEHRINGER INGELHEIM | |
| Abstract Number | 6019 |
| Title | “An open-label, Phase Ib trial of the SIRPα inhibitor BI 765063 in combination with ezabenlimab and cetuximab in patients with head and neck squamous cell carcinoma” |
| Session Type and Title | Rapid Oral Abstract - Head and Neck Cancer |
| Date and time | June 1, 2025 - 11:30 AM - 1:30 PM CDT |
The abstract summaries will be available on ASCO website on Thursday, May 22, 2025.
ABOUT OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is quoted on Euronext.
Additional information about OSE Immunotherapeutics assets is available on the Company’s website: . Follow us on LinkedIn.
Contacts
| Fiona Olivier Sylvie Détry | French Media Contact FP2COM Florence Portejoie +33 6 07 768 283 | U.S. Media Contact Rooney Partners LLC Kate Barrette |
Forward-looking statements
This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics’ management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.
These forward-looking statements include statements typically using conditional and containing verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics’ shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2024, including the annual financial report for the fiscal year 2023, available on the OSE Immunotherapeutics’ website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.
Attachment
